Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors

Abstract

Aim: We report an exploratory analysis of cfRNA as a biomarker to monitor clinical responses in non-small cell lung cancer (NSCLC), breast cancer, and colorectal cancer (CRC). An analysis of cfRNA as a method for measuring PD-L1 expression with comparison to clinical responses was also performed in the NSCLC cohort.

Methods: Blood samples were collected from 127 patients with metastatic disease that were undergoing therapy, 52 with NSCLC, 50 with breast cancer, and 25 with CRC. cfRNA was purified from fractionated plasma, and following reverse transcription (RT), total cfRNA and gene expression of PD-L1were analyzed by real-time polymerase chain reaction (qPCR) using beta-actin expression as a surrogate for relative amounts of cfDNA and cfRNA. For the concordance study of liquid biopsies and tissue biopsies, the isolated RNA was analyzed by RNAseq for the expressions of 13 genes. We had to close the study early due to a lack of follow-up during the Covid-19 pandemic.

Results: We collected a total of 373 blood samples. Mean cfRNA PCR signals after RT were about 50-fold higher than those of cfDNA. cfRNA was detected in all patients, while cfDNA was detected in 88% of them. A high concordance was found for the expression levels of 13 genes between blood and solid tumor tissue. Changes in cfRNA levels followed over the course of treatments were associated with response to therapy, increasing in progressive disease (PD) and falling when a partial response (PR) occurred. The expression of PD-L1 over time in patients treated with immunotherapy decreased with PR but increased with PD. Pre-treatment levels of PD-L1 were predictive of response in patients treated with immunotherapy.

Conclusion: Changes in cfRNA correlate with clinical response to the therapy. Total cfRNA may be useful in predicting clinical outcomes. PD-L1 gene expression may provide a biomarker to predict response to PD-L1 inhibition.

Keywords

cfRNA / cfDNA / liquid biopsies / NSCLC / PD-L1

References

[1] Fey MF.Tumour heterogeneity and clonality--an old theme revisited.Ann Oncol1996;7:121-8

[2] Rolfo C,Hong D.Liquid biopsies in lung cancer: the new ambrosia of researchers.Biochim Biophys Acta2014;1846:539-46

[3] Crowley E,Loupakis F.Liquid biopsy: monitoring cancer-genetics in the blood.Nat Rev Clin Oncol2013;10:472-84

[4] Diaz LA Jr.Liquid biopsies: genotyping circulating tumor DNA.J Clin Oncol2014;32:579-86 PMCID:PMC4820760

[5] Umetani N,Hiramatsu S.Increased integrity of free circulating DNA in sera of patients with colorectal or periampullary cancer: direct quantitative PCR for ALU repeats.Clin Chem2006;52:1062-9

[6] Kuang Y,Yeap BY.Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer.Clin Cancer Res2009;15:2630-6 PMCID:PMC2727796

[7] Jian G,Ling Z.Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer.J Cancer Res Clin Oncol2010;136:1341-7

[8] Taniguchi K,Nishino K.Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.Clin Cancer Res2011;17:7808-15

[9] Gautschi O,Ziegler A.Origin and prognostic value of circulating KRAS mutations in lung cancer patients.Cancer Lett2007;254:265-73

[10] Sawyers CL.The cancer biomarker problem.Nature2008;452:548-52

[11] Osumi H,Yamaguchi K.Early change in circulating tumor DNA as a potential predictor of response to chemotherapy in patients with metastatic colorectal cancer.Sci Rep2019;9:17358 PMCID:PMC6874682

[12] Bettegowda C,Leary RJ.Detection of circulating tumor DNA in early- and late-stage human malignancies.Sci Transl Med2014;6:224ra24 PMCID:PMC4017867

[13] Herbst RS,Kowanetz M.Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.Nature2014;515:563-7 PMCID:PMC4836193

[14] Hamanishi J,Iwasaki M.Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.Proc Natl Acad Sci U S A2007;104:3360-5 PMCID:PMC1805580

[15] Topalian SL,Brahmer JR.Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.N Engl J Med2012;366:2443-54 PMCID:PMC3544539

[16] Brahmer JR,Chow LQ.Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.N Engl J Med2012;366:2455-65 PMCID:PMC3563263

[17] Ishiba T,Usher J.Frequencies and expression levels of programmed death ligand 1 (PD-L1) in circulating tumor RNA (ctRNA) in various cancer types.Biochem Biophys Res Commun2018;500:621-5

[18] Raez L,Sumarriva D.PD2.01 PD-L1 and other potential predictive biomarkers measured in plasma by RT-PCR in cfRNA and cfDNA to monitor clinical responses in metastatic lung cancer patients.J Thorac Oncol2019;14:S1170

[19] Wan JCM,Garcia-Corbacho J.Liquid biopsies come of age: towards implementation of circulating tumour DNA.Nat Rev Cancer2017;17:223-38

[20] Volckmar AL,Riediger A.A field guide for cancer diagnostics using cell-free DNA: from principles to practice and clinical applications.Genes Chromosomes Cancer2018;57:123-39

[21] Hu Y,Supplee J.False-positive plasma genotyping due to clonal hematopoiesis.Clin Cancer Res2018;24:4437-43

[22] Larson MH,Kim HJ.A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection.Nat Commun2021;12:2357 PMCID:PMC8060291

[23] Kamm R.Ribonuclease activity in human plasma.Clin Biochem1972;5:198-200

[24] Kopreski MS,Kwak LW.Detection of tumor messenger RNA in the serum of patients with malignant melanoma.Clin Cancer Res1999;5:1961-5

[25] Kopreski MS,Gocke CD.Circulating RNA as a tumor marker: detection of 5T4 mRNA in breast and lung cancer patient serum.Ann N Y Acad Sci2001;945:172-8

[26] Das K,Alt JR,Williams TL.Stabilization of cellular RNA in blood during storage at room temperature: a comparison of cell-free RNA BCT(®) with K3EDTA tubes.Mol Diagn Ther2014;18:647-53 PMCID:PMC4245490

[27] Abbosh C,Swanton C.Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection.Nat Rev Clin Oncol2018;15:577-86

[28] Peters S,Perol M.VP2-2021: Effectiveness of PD-(L)1 inhibitors alone or in combination with platinum-doublet chemotherapy in first-line (1L) non-squamous non-small cell lung cancer (Nsq-NSCLC) with high PD-L1 expression using real-world data.Ann Oncol2021;32:687-8